Information on this blog is being shared only for the purpose of creating legal awareness in public at large, especially in the field of Intellectual Property Right. As there may be possibility of error, omission or mistake in legal interpretation on the contents of this blog, it should not be treated as substitute for legal advise.
Tuesday, February 11, 2025
Anil Kamath Vs. Vasu Naik N.
Star India Pvt. Ltd. v. IPTV Smarters Pro
Mac Laboratories Private Ltd. Vs. American Home Products Corporation
Godfrey Phillips India Ltd. Vs. Girnar Food & Beverages Pvt. Ltd.
Boehringer Ingelheim Pharma GmbH Vs. Vee Excel Drugs and Pharmaceuticals Pvt. Ltd.
Boehringer Ingelheim Pharma GmbH & Co. KG & Anr. filed multiple suits before the Delhi High Court against various Indian pharmaceutical companies, including Vee Excel Drugs and Pharmaceuticals Pvt. Ltd., seeking a permanent injunction to restrain the defendants from infringing Indian Patent No. IN 243301. The case, CS(COMM) 239/2019 and connected matters, was adjudicated by Hon’ble Mr. Justice Amit Bansal, with the judgment reserved on 27th January 2023 and delivered on 29th March 2023. The neutral citation for the judgment is 2023:DHC:2272. The plaintiffs contended that the defendants were manufacturing and selling Linagliptin-based pharmaceutical products, thereby infringing their patent covering "8-(3-AMINOPIPERIDIN–1–YL)-XANTHINE COMPOUNDS." They argued that the patent was validly granted and that their rights under Section 48 of the Patents Act, 1970, entitled them to an exclusive monopoly over Linagliptin formulations in India. The plaintiffs had previously obtained an interim injunction restraining the defendants from manufacturing and selling Linagliptin tablets.
The defendants countered that the plaintiffs' patent IN 243301 was an attempt at "evergreening," as Linagliptin had already been claimed in an earlier genus patent, IN 227719, which expired on 21st February 2022. They asserted that the plaintiffs were attempting to extend their monopoly beyond the permissible twenty-year patent term by obtaining a species patent that covered the same invention as the genus patent. The defendants also challenged the validity of the plaintiffs' patent under multiple provisions of the Patents Act, including Section 64(1)(a) (prior claiming), Section 64(1)(f) (lack of inventive step), and Section 3(d) (mere discovery of a new form of a known substance). They argued that Linagliptin, as a Markush structure, was already disclosed and protected under the earlier patent, and thus, any attempt to extend its exclusivity was impermissible.
The plaintiffs, in response, submitted that Linagliptin was specifically claimed only in the species patent IN 243301 and was distinct from the broader genus patent IN 227719. They contended that the suit patent had been successfully enforced in multiple jurisdictions, including China, and that no pre-grant or post-grant oppositions had been filed against it. They further argued that once a patent was granted, the onus was on the defendants to demonstrate its invalidity with cogent evidence. The plaintiffs relied on the judgment in FMC Corporation & Anr. v. Best Crop Science LLP & Anr., (2021) 87 PTC 217, to argue that merely raising a challenge was insufficient to deny an injunction unless the challenge was credible. They also cited National Research Development Corp. of India v. Delhi Cloth & General Mills, (1979 SCC OnLine Del 206), to claim that old patents with established commercial success should be presumed valid for interim relief purposes.
The defendants, on the other hand, relied on AstraZeneca AB & Anr. v. Intas Pharmaceuticals Ltd., (2021) 87 PTC 374 (DB), to argue that the suit patent was vulnerable to revocation due to prior claiming and evergreening. They contended that the plaintiffs had admitted in multiple proceedings worldwide that Linagliptin was covered under IN 227719. They emphasized that Linagliptin was the only commercial embodiment of both patents, as evidenced by the plaintiffs' identical Form 27 working statements for IN 227719 and IN 243301.
The court analyzed whether an older patent should be presumed valid for granting an interim injunction. Referring to Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries, AIR 1982 SC 1444, the court reaffirmed that Section 13(4) of the Patents Act does not warrant the validity of a patent merely because it has been granted. The court also rejected the six-year rule discussed in National Research Development Corp. (supra), stating that in India, the presumption of validity does not arise merely due to a patent's age or commercial success. The judgment in F. Hoffmann-La Roche & Anr. v. Cipla Ltd., ILR(2009)Supp.(2)Delhi 551, was cited to emphasize that even patents that survive pre-grant and post-grant oppositions can still be challenged on new grounds in revocation proceedings.
The court then examined the issue of prior claiming under Section 64(1)(a). It noted that a species patent could be invalidated if the genus patent had already claimed the same subject matter. A comparative analysis of the claims of IN 227719 and IN 243301 showed substantial structural similarity, leading to the conclusion that Linagliptin was indeed covered by the genus patent. The court also referred to the International Search Report (ISR) of the PCT application for IN 243301, which categorized the genus patent as an ‘X’ reference, indicating that Linagliptin lacked novelty and inventive step. The court found this persuasive evidence that the plaintiffs’ claim of Linagliptin being separately patentable was untenable.
On the issue of evergreening under Section 3(d), the court analyzed whether the plaintiffs had demonstrated any enhanced efficacy of Linagliptin over the broader genus patent. The court cited Novartis AG v. Union of India, (2013) 6 SCC 1, where the Supreme Court held that mere discovery of a new form of a known substance without improved therapeutic efficacy is not patentable. The plaintiffs failed to show any significant enhancement in efficacy, leading the court to conclude that the suit patent was vulnerable under Section 3(d).
The court held that the defendants had established a credible challenge to the validity of the suit patent. Following the standard laid down in F. Hoffmann-La Roche v. Cipla (supra), it ruled that a credible challenge at the interim stage is sufficient to deny an injunction. The court found that the balance of convenience lay in favor of the defendants, as the plaintiffs had already enjoyed a twenty-year monopoly under IN 227719. Additionally, the defendants' Linagliptin-based products were significantly cheaper than the plaintiffs' imported versions, making affordability and public interest key considerations. The court also noted that monetary damages would be an adequate remedy if the plaintiffs ultimately succeeded at trial.
Consequently, the Delhi High Court denied the plaintiffs’ application for an interim injunction, allowing the defendants to continue manufacturing and selling Linagliptin products.
Svamaan Financial Services Vs Samman Capital Services
Sunday, February 9, 2025
Aditya Birla Fashion & Retail Ltd. Vs Friends Inc
IMS Learning Resources Pvt. Ltd. Vs. Young Achievers
Sahil Parvez Vs. Union of India
Bharat Singh Vs. Karan Singh
Advocate Ajay Amitabh Suman
[Patent and Trademark Attorney]
High Court of Delhi
Disclaimer:The information shared here is intended to serve the public interest by offering insights and perspectives. However, readers are advised to exercise their own discretion when interpreting and applying this information. The content herein is subjective and may contain errors in perception, interpretation, and presentation.
Pidilite Industries Ltd. Vs. Astra Chemtech Private Ltd.
Friday, February 7, 2025
Tractors and Farm Equip Ltd. Vs. Massey Ferguson Corp.
Anshul Vaish Vs Hari Om and Co.
Natco Pharma Ltd. Vs Kudos Pharma Ltd.
Blog Archive
- March 2025 (55)
- February 2025 (116)
- January 2025 (58)
- October 2024 (8)
- September 2024 (34)
- August 2024 (68)
- July 2024 (39)
- June 2024 (57)
- May 2024 (49)
- April 2024 (6)
- March 2024 (44)
- February 2024 (39)
- January 2024 (21)
- December 2023 (29)
- November 2023 (23)
- October 2023 (27)
- September 2023 (33)
- August 2023 (29)
- July 2023 (29)
- June 2023 (2)
- May 2023 (1)
- April 2023 (5)
- March 2023 (6)
- February 2023 (1)
- November 2022 (17)
- October 2022 (11)
- September 2022 (30)
- August 2022 (47)
- July 2022 (37)
- June 2022 (26)
- October 2020 (1)
- September 2020 (1)
- April 2020 (1)
- March 2020 (1)
- February 2020 (2)
- December 2019 (1)
- September 2019 (3)
- August 2019 (2)
- July 2019 (1)
- June 2019 (2)
- April 2019 (3)
- March 2019 (2)
- February 2019 (2)
- January 2019 (2)
- December 2018 (3)
- November 2018 (1)
- October 2018 (2)
- September 2018 (2)
- August 2018 (8)
- July 2018 (2)
- June 2018 (1)
- May 2018 (41)
- April 2018 (7)
- March 2018 (3)
- February 2018 (4)
- January 2018 (2)
- December 2017 (6)
- November 2017 (4)
- September 2017 (5)
- August 2017 (6)
- July 2017 (1)
- June 2017 (1)
- May 2017 (10)
- April 2017 (16)
- November 2016 (3)
- October 2016 (24)
- March 2015 (2)
- January 2014 (1)
- December 2013 (4)
- October 2013 (2)
- September 2013 (7)
- August 2013 (27)
- May 2013 (7)
- September 2012 (31)
- December 2009 (3)
- September 2009 (1)
- March 2009 (3)
- January 2009 (2)
- December 2008 (1)
Featured Post
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK REGISTRA...
-
$~5 * IN THE HIGH COURT OF DELHI AT NEW DELHI + FAO 317/2018, CAV 617/2018 & CM AP...
-
$~20 * IN THE HIGH COURT OF DELHI AT NEW DELHI + CS(OS) 645/2015 & I.A.Nos.4941...
My Blog List
-
कॉफी बनाम चाय युद्ध – एक अदालत में टकराव - कॉफी बनाम चाय युद्ध – एक अदालत में टकराव अदालत में दो वकील, श्रीमान A और श्रीमान B, एक बेहद गर्मागर्म बहस में उलझे हुए थे। आवाज़ें इतनी ऊँची हो चुकी थीं कि...1 day ago
-
Deepfake Technology: Unveiling The Challenges And Protective Measures - Introduction: The rapid evolution of technology has propelled humanity into an era of unprecedented progress and connectivity. However, as with any doubl...1 year ago
-
-
My other Blogging Links
- Ajay Amitabh Suman's Poem and Stories
- Facebook-My Judgments
- Katha Kavita
- Lawyers Club India Articles
- My Indian Kanoon Judgments
- Linkedin Articles
- Speaking Tree
- You Tube-Legal Discussion
- बेनाम कोहड़ा बाजारी -Facebook
- बेनाम कोहड़ा बाजारी -वर्ड प्रेस
- बेनाम कोहड़ा बाजारी-दैनिक जागरण
- बेनाम कोहड़ा बाजारी-नवभारत टाइम्स
- बेनाम कोहड़ा बाजारी-ब्लॉग स्पॉट
- बेनाम कोहड़ा बाजारी-स्पीकिंग ट्री